 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Alpelisib combined with trastuzumab and LJM716 in the treatment of PIK3CA mutant HER2-positive metastatic breast cancer

Clin Cancer Res: Alpelisib combined with trastuzumab and LJM716 in the treatment of PIK3CA mutant HER2-positive metastatic breast cancer

 Last Update: 2021-07-27
 Source: Internet
 Author: User

Tags

journal immunotherapy cancer

cadasil treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

PIK3CA activating mutations can promote breast cancer resistance to HER2 targeted therapy

Breast cancer

This is a phase I study investigating the MTD of Alpelisib combined with trastuzumab and LJM716 (HER3 targeting antibody) for HER2-positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation

Treatment remission of each group

Ten patients in group A initially received Alpelisi treatment daily

In group B, 11 patients received intermittent Alpelisib treatment with an MTD of 350 mg for 4 consecutive days, and then the drug was discontinued for 3 days

Of the 17 evaluable patients, 1 had a partial remission, 14 had a stable condition, and 2 had disease progression at the time of the best response

In summary, the combination therapy of Alpelisib, trastuzumab and LJM716 is limited by gastrointestinal toxicity

Original source:

Komal Jhaveri, et al.

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Erlotinib hydrochloride

CAS No.: 183319-69-9

Industrial Grade or Medical grade

$1/MT EXW

6-Thioguanine

CAS No.: 154-42-7

Industrial Grade or Medical grade

$1/MT EXW

Vinblastine sulfate

CAS No.: 143-67-9

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.